NMRA vs. ADMA, SANA, FDMT, INBX, FUSN, TARS, VIR, BEAM, CGEM, and SRRK
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include ADMA Biologics (ADMA), Sana Biotechnology (SANA), 4D Molecular Therapeutics (FDMT), Inhibrx (INBX), Fusion Pharmaceuticals (FUSN), Tarsus Pharmaceuticals (TARS), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Cullinan Oncology (CGEM), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
ADMA Biologics (NASDAQ:ADMA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
In the previous week, ADMA Biologics had 16 more articles in the media than Neumora Therapeutics. MarketBeat recorded 28 mentions for ADMA Biologics and 12 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.58 beat ADMA Biologics' score of 0.40 indicating that ADMA Biologics is being referred to more favorably in the media.
ADMA Biologics received 395 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 71.68% of users gave ADMA Biologics an outperform vote.
Neumora Therapeutics has a net margin of 0.00% compared to Neumora Therapeutics' net margin of -10.94%. Neumora Therapeutics' return on equity of 0.49% beat ADMA Biologics' return on equity.
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ADMA Biologics has higher revenue and earnings than Neumora Therapeutics.
ADMA Biologics presently has a consensus target price of $10.50, suggesting a potential upside of 19.18%. Neumora Therapeutics has a consensus target price of $22.57, suggesting a potential upside of 145.61%. Given ADMA Biologics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than ADMA Biologics.
Summary
ADMA Biologics beats Neumora Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
